- host disease compared to 42 percent of patients who typically develop this condition with standard medications alone. (sciencedaily.com)
A Phase III Randomized Open - Label Multi-Center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid - Refractory Chronic Graft vs Host Disease after Allogenic Stem Cell Transplantation (REACH 3) (vicc.org)
Besides the ethical concerns of stem cell therapy, there is a technical problem of graft - versus - host disease associated with allogeneic stem cell transplantation. (sciencedaily.com)